Is Illumina (ILMN) Quietly Recasting Its Clinical Genomics Strategy With Eli Lilly’s R&D Chief on Board?
Illumina recently appointed Daniel M. Skovronsky, Eli Lilly’s Chief Scientific and Product Officer, to its board, potentially influencing its clinical genomics and next-generation sequencing strategy. This move aligns with Illumina's focus on clinical applications like minimal residual disease and TruPath Genome, which are crucial for higher-value clinical use cases and recurring consumables. Despite the clinical opportunities, the company still faces risks from export restrictions and regulatory pressures in China.
(ILMN) Risk Channels and Responsive Allocation
This article analyzes Illumina Inc. (ILMN), indicating a strong overweight bias across all time horizons based on AI models. It highlights the absence of resistance levels above the current price, suggesting significant upside potential. Three distinct trading strategies are presented, tailored for different risk profiles, along with multi-timeframe signal analysis for near-term, mid-term, and long-term outlooks.
Should You Continue to Hold ILMN Stock in Your Portfolio?
Illumina Inc. (ILMN) is poised for growth due to its focus on core sequencing, multiomics expansion, and strong NovaSeq X placements, despite challenges in the China market and macroeconomic pressures. The company surpassed Q1 2026 estimates, raised full-year guidance, and sees clinical end markets as a key driver for demand. Analysts forecast continued revenue and EPS growth, making ILMN a Zacks Rank #3 (Hold) stock.
Price to sales forward of Illumina, Inc. – NASDAQ:ILMN
This article provides access to the "Price to sales forward" metric for Illumina, Inc. (NASDAQ: ILMN) on the TradingView platform. It is a financial data point for the health technology company. The content appears to be a truncated view of a financial data page rather than a detailed analytical article.
Form 4 Illumina Inc For: 2 July By Investing.com
This article reports on a Form 4 filing for Illumina Inc. dated July 2nd. It notes a 2.60% increase in ILMN stock and provides an overview of various financial market data including indices, commodities, bonds, and trending stocks. The content is presented by Investing.com, a financial markets website.
[Form 4] ILLUMINA, INC. Insider Trading Activity
ILLUMINA, INC. director Scott B. Ullem reported an acquisition of 167 shares of common stock on June 30, 2026, as compensation for his second-quarter board and committee retainer fees. The shares, valued at $149.1868 each, were granted based on the volume-weighted average closing price. Following this transaction, Ullem directly holds 11,030 shares of Illumina common stock.
Illumina (ILMN) director takes 2026 board fees entirely in stock
Illumina director Keith A. Meister has opted to receive 100% of his 2026 board and committee cash retainer fees in company stock. For the second quarter of 2026, this resulted in a grant of 142 shares at a reference price of $149.1868 per share, increasing his direct holdings to 6,780 shares. He also indirectly holds over 2.8 million additional shares through Corvex-advised private investment funds.
ILMN - Illumina Inc Volatility & Greeks
This article provides a detailed snapshot of Illumina Inc. (ILMN) financial and stock performance data as of July 2, 2026. It includes key metrics such as market capitalization, income, sales, various P/E ratios, EPS growth rates, insider and institutional ownership, profitability margins, and volatility indicators. The data highlights recent price changes, trading volumes, and performance over different periods.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) stock increased by 2.60% to $188.68 on Thursday, outperforming the S&P 500 Index and the Dow Jones Industrial Average on a mixed trading day. This marks the second consecutive day of gains for the company's shares.
Illumina (ILMN) Gets Bernstein’s Market Perform Rating Amid NovaSeq X Recovery
Bernstein SocGen analyst Eve Burstein has resumed coverage of Illumina (NASDAQ: ILMN) with a Market Perform rating and a $185 price target, citing the company's recovery from a difficult period. Illumina faced challenges in early 2025 due to China restricting imports of its sequencing instruments but has since recovered by focusing on its NovaSeq X sequencer and expanding clinical applications. The life sciences sector, including Illumina, is also benefiting from new drug approvals, trial starts, and increased funding, particularly driven by AI demand for semiconductor-related tools.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock advance 4.58% to $183.89, outperforming the broader market during a challenging trading session where the S&P 500 and Dow Jones Industrial Average both declined. The company also reached a new 52-week high, surpassing its previous peak from June 25th.
Piper Sandler raises Illumina stock price target on clinical strength
Piper Sandler increased its price target for Illumina (NASDAQ:ILMN) to $200 from $170, maintaining an Overweight rating, based on the company's strong clinical business momentum and dominance in the genomics market. The firm highlighted Illumina's NovaSeq X system, which accounts for 90% of high-throughput gigabases shipped, enabling clinical-scale multiomics. This shift towards high-quality, reimbursed clinical consumables, which grew 20% year-over-year in Q1 2026, is seen as decoupling Illumina's growth from the volatile academic research market.
Roche takes on Illumina with new NGS system
Roche is entering the next-generation sequencing market with its new Axelios 1 system, directly challenging Illumina's long-standing dominance. The Axelios 1 platform utilizes a novel "sequencing by expansion" (SBX) technology, which Roche claims offers improved accuracy, scalability, and speed for genomics research and potential clinical applications. While analysts acknowledge the intrigue of Roche's technology, they emphasize Illumina's strong market position and customer loyalty as significant barriers to rapid market disruption.
Price to earnings forward of Illumina, Inc. – TURQUOISE:ILMNN
This article displays the "Price to earnings forward" value for Illumina, Inc. (ILMNN) on the Turquoise market. It indicates that the market is currently closed with no trades. The data is provided by ICE Data Services and FactSet Research Systems Inc.
Roche Launches AXELIOS 1 Sequencer At $750,000, Targeting Illumina’s Market
Roche has launched its new AXELIOS 1 Sequencer, priced at $750,000, directly challenging Illumina's market dominance. The sequencer is capable of generating reads up to 1,500 base pairs, positioning Roche as a significant competitor in the genomics sequencing industry. This move signals an intensifying race in the diagnostics sector.
Illumina, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh Actuals & Estimates (BMFBOVESPA:I1LM34)
This page provides financial actuals and estimates for Illumina, Inc. Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh (BMFBOVESPA:I1LM34) on TradingView. Users can explore reported financial data and analyst estimates, comparing actual results with average, high, and low estimates across various financial statements and valuation metrics. The platform also visualizes trends over time for informed decision-making.
Insider Sell: Scott Davies Sells Shares of Illumina Inc (ILMN)
Scott Davies, Chief Legal Officer of Illumina Inc's subsidiary, sold 615 shares of Illumina Inc (ILMN) on June 25, 2026. This transaction brings his total holdings to 20,953 shares. The stock is currently trading at $180, significantly above its GF Value of $129.16, indicating it is overvalued.
Illumina (NASDAQ: ILMN) legal chief sells 615 shares in open-market trade
Illumina's Chief Legal Officer, Scott M. Davies, sold 615 shares of the company's common stock at $180 per share in an open-market transaction. This sale, totaling $110,700, represents a small portion of his overall direct holdings, which now stand at 20,953 shares. The transaction was reported via a Form 4 filing with the SEC and is categorized as a moderate impact with negative sentiment by Rhea-AI.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) stock increased by 1.46% to $177.65, marking its third consecutive day of gains. This performance occurred on a mixed trading day where the Dow Jones Industrial Average rose by 0.14%, while the S&P 500 Index fell by 0.01%. The article highlights Illumina's strong performance relative to the broader market and its competitors.
Illumina (NASDAQ: ILMN) affiliate files Form 144 reporting 98,400-share 10b5-1 sale
An Illumina (NASDAQ: ILMN) affiliate has filed Form 144 to report the proposed sale of 98,400 common shares. The filing details a 10b5-1 sale on May 29, 2026, linked to Performance Stock Units and Restricted Stock Units granted on February 21, 2023. This is a regulatory notice of intent to sell rather than a confirmed transaction.
Frances Arnold sells Illumina shares (ILMN) in multiple May–June 2026 trades
Frances Arnold reported proposed sales of Illumina (ILMN) common stock through a Form 144 filing, detailing multiple dispositions in May–June 2026. These include sales of 3,000 shares on June 2, 2026, for $484,571.70 and 5,000 shares on May 28, 2026, for $780,650.00. The filing also noted the vesting of 2,000 restricted shares on May 21, 2026, under a registered compensation plan.
Illumina Jumps 7.7% Amid Sector-Wide Rally
Illumina (ILMN) saw its stock surge by 7.7% on Wednesday, closing at $177.66, driven by a broad sector-wide rally in diagnostics and research stocks. This gain was part of a larger trend, with several other life sciences companies also experiencing significant increases. The rally indicates renewed investor confidence in the life sciences tools and diagnostics sector.
Illumina (ILMN) director Daniel Skovronsky receives 1,674-share RSU grant
Illumina director Daniel Skovronsky received a grant of 1,674 restricted stock units (RSUs), valued at $164.28 per share, representing his total direct holding after this transaction. The RSUs will vest entirely on the earlier of one year from the grant date or the date immediately preceding the next annual stockholder meeting, contingent on his continued service as a director. This transaction is a form of compensation and not a market purchase.
Why Illumina (ILMN) Stock Is Trading Up Today
Illumina's stock (ILMN) surged 6.6% after the company appointed Daniel M. Skovronsky, a high-profile Eli Lilly executive, to its board of directors. Barclays also increased its price target for Illumina to $145 from $122, noting that life science and diagnostic tools are gaining favor among healthcare subsectors. Despite the year-to-date gain, the stock remains volatile, with a significant increase in the third quarter of 2025 due to better-than-expected earnings and raised full-year guidance.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock rise by 6.16% on Wednesday, closing at $175.09. This performance occurred on a mixed trading day where the Dow Jones Industrial Average gained 0.35%, and the S&P 500 Index fell 0.10%. This marks the second consecutive day of gains for Illumina's stock.
Illumina CEO: Chasing challenges & transforming global health
Illumina CEO Jacob Thaysen discusses his journey into leadership and how his drive to solve complex challenges has shaped Illumina's mission to transform global health through genomics. He emphasizes Illumina's commitment to advancing care, expanding access, and delivering impactful solutions in areas like cancer and rare diseases. The conversation highlights how Illumina is evolving its genomic workflows to make insights more actionable and accessible, especially with advancements in AI.
Illumina stock hits 52-week high at 177.76 USD
Illumina Inc.'s stock recently hit a 52-week high of $159.45, reflecting an 80.18% increase over the past year and strong investor confidence. The company boasts a gross profit margin of 68.29% on $4.39 billion revenue and has recently launched new research platforms and appointed a new board member. Guggenheim has raised its price target for Illumina shares to $180, citing the company's pricing power and growth potential.
How Investors May Respond To Illumina (ILMN) Adding Eli Lilly R&D Chief To Its Board
Illumina has appointed Daniel M. Skovronsky, Eli Lilly's Chief Scientific and Product Officer, to its board, aiming to strengthen its expertise in genomics, multiomics, and precision medicine. This move is expected to reinforce Illumina's clinical and multiomics positioning, a key part of its growth strategy, though it doesn't significantly alter near-term drivers like execution challenges and competition. While analysts have varying forecasts for Illumina's future revenue and earnings, the appointment of a seasoned R&D leader could potentially support more optimistic views or lead to a re-evaluation of current projections.
Illumina (ILMN) director Daniel Skovronsky files initial insider Form 3
Illumina director Daniel Skovronsky has filed an initial Form 3, indicating his new status as an insider with the company. This filing is a statement of beneficial ownership and does not report any buy or sell transactions. Its purpose is to officially record his insider status with regulators, laying the groundwork for any future reporting of trading activity.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock price rise by 2.20% to $164.93 on Tuesday, an impressive performance given the overall down day for the stock market. Both the S&P 500 Index and Dow Jones Industrial Average experienced declines. Despite the gain, Illumina Inc. is still trading 6.93% below its 52-week high.
Illumina adds Eli Lilly executive to board of directors
Illumina Inc. has appointed Daniel M. Skovronsky, Chief Scientific and Product Officer of Eli Lilly and Company, to its board of directors, effective June 16. This move follows strong performance by Illumina's shares, which hit a 52-week high after an 80% gain over the past year. Skovronsky's extensive experience in scientific expertise, innovation leadership, and healthcare impact is expected to strengthen Illumina's drive for innovation in genomics and precision medicine.
Illumina adds Daniel M. Skovronsky to its Board
Illumina has appointed Daniel M. Skovronsky, M.D., Ph.D., as an independent director to its Board of Directors, effective June 16, 2026. This appointment expands the board size from nine to ten members. Dr. Skovronsky meets the independence requirements of Nasdaq and SEC rules and will stand for election at the 2027 annual meeting.
Form 8K Illumina Inc For: 23 June By Investing.com
This article announces that Illumina Inc. has filed a Form 8K on June 23. It includes market data for various indices, commodities, and individual stocks, as well as several related news headlines. The content primarily serves as a placeholder for the SEC filing announcement and market overview.
Illumina (NASDAQ: ILMN) appoints Eli Lilly R&D leader to its board
Illumina has expanded its Board of Directors from nine to ten members, appointing Daniel M. Skovronsky, M.D., Ph.D., as a new director, effective June 16, 2026. Dr. Skovronsky, who is currently Chief Scientific and Product Officer at Eli Lilly, brings extensive experience in drug discovery and clinical development relevant to Illumina's genomics platforms. He will stand for election at the company's 2027 annual meeting and will be compensated under Illumina's non-employee director programs.
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Illumina, Inc. has appointed Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky, who is currently Chief Scientific and Product Officer at Eli Lilly and Company, brings extensive experience in drug discovery, clinical development, and translational medicine. His expertise is expected to strengthen Illumina's innovation in genomics, multiomics, and precision medicine.
The DRAGEN v4.3 from Illumina Inc. - new pipelines push clinical sequencing speed
Illumina Inc. has launched DRAGEN v4.3, an update to its hardware-accelerated secondary analysis platform designed to significantly reduce turnaround times for whole genome and oncology sequencing. This new version offers faster processing for clinical and research labs, directly impacting patient diagnostics for rare diseases and oncology. While praised for its speed and accuracy, some users find its management consoles and update protocols challenging, highlighting Illumina's strategy to maintain its market position against intensifying competition.
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist
IQM Quantum Computers has appointed Dr. Craig Ciesla as Chief Technology Officer and Dr. Inés de Vega as Chief Scientist. Ciesla, with extensive experience in deep tech and product development, will lead IQM's technology strategy, while de Vega will ensure scientific feasibility and system-level consistency. These strategic appointments come as IQM scales its operations and prepares for a Nasdaq listing through a merger with Real Asset Acquisition Corp.
Video: Prof. Emma Baple on bringing whole-genome sequencing into clinical research
Professor Emma Baple, a genomic medicine expert, discusses the integration of whole-genome sequencing into clinical research at the European Society of Human Genetics 2026 conference. She highlights the benefits of genomic sequencing and its potential to improve outcomes for critically ill patients. Illumina also presented research on their TruPath™ Genome solution, demonstrating the robustness and accessibility of whole-genome sequencing across various real-world sample types.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock rise by 1.79% to $161.93, outperforming the broader market during a strong trading session where the S&P 500 Index and Dow Jones Industrial Average also gained. This increase ended a two-day losing streak for the company's shares.
Illumina Inc (ILMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Illumina Inc (ILMN), segmenting its revenue by business and by region. As of April 6 (with data updated for FY2025), Consumables account for 74.30% of revenue, followed by Services and Other revenue at 14.60%, and Instruments at 11.10%. Regionally, the United States contributes the most at 51.65%, with Europe being the second-largest market at 29.10%.
Illumina Inc (ILMN) Shares Fall 3.2% -- GF Value Says Still Overvalued
Illumina Inc (ILMN) shares dropped 3.2% on June 17, 2026, bringing its price to $159.09, despite a significant year-over-year increase of 77.8%. According to GuruFocus' GF Value, the stock is considered 23.3% overvalued, with an estimated intrinsic value of $129.00. Insider activity shows $155.7 million in shares sold over the last three months with no buying, potentially signaling a lack of insider confidence in its future performance at current valuations.
Illumina Connected Analytics brings clinical-grade genomics to the cloud for hospitals and labs
Illumina has launched Illumina Connected Analytics, a cloud-native genomics platform designed for hospitals, research labs, and diagnostics providers. This service aims to provide clinical-grade security and scalability for analyzing sequencing data without requiring organizations to build their own infrastructure. The platform streamlines workflows from raw sequencing data to clinical reports, ensuring data security through features like role-based access control and compliance with healthcare security standards.
Illumina Inc. stock underperforms Tuesday when compared to competitors
Illumina Inc. (ILMN) stock dropped 1.56% on Tuesday, closing at $164.28, in a mixed trading session where the Dow Jones Industrial Average rose and the S&P 500 Index fell. This performance left Illumina 7.30% below its 52-week high of $177.22, achieved on June 4th. The article highlights the stock's underperformance relative to key market indices and its competitors.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock rally by 3.68% to $166.89 on Monday, outperforming the broader market despite a strong trading session for both the S&P 500 and Dow Jones Industrial Average. The company's shares closed 5.83% below its 52-week high.
What is proteomics? A simple guide to understanding measuring proteins at scale
Proteomics is the large-scale study of proteins, which are crucial for nearly all functions in living organisms. Unlike the static genome, the proteome is dynamic, changing across different cell types and conditions, offering insights into real-time biological activity that DNA or RNA analysis alone cannot capture. This field is vital for understanding disease mechanisms, identifying biomarkers, and developing new therapeutic targets through its ability to quantify proteins, analyze their structure and modifications, and map biological pathways.
Liquidity Mapping Around (ILMN) Price Events
This article provides a liquidity mapping analysis for Illumina Inc. (NASDAQ: ILMN), highlighting a weak near-term sentiment that could lead to shifts in mid and long-term outlook. It identifies an exceptional 37.1:1 risk-reward short setup and outlines three AI-generated trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
Illumina Inc (ILMN) Stock Down 3.1% but Still Overvalued -- GF S
Illumina Inc. (ILMN) stock dropped 3.1% to $160.97 but is considered 24.9% overvalued according to GuruFocus' GF Value of $128.90. The company has a GF Score of 76/100, indicating solid fundamentals, yet insider activity shows a significant sell-off of $155.7 million with no buying, signaling potential caution for investors. Despite a P/E ratio below its historical median, the stock's intrinsic value suggests overvaluation.
When sequencing isn’t enough: A global forum for finding answers
This article discusses the challenges faced in interpreting genomic data even after successful sequencing, particularly with rare variants or variants of uncertain significance (VUS). It highlights the growing importance of reanalysis, tertiary analysis in oncology, and the integration of broader contextual information and multidisciplinary expertise. The piece also notes the role of AI in streamlining interpretation workflows and introduces Illumina's Grand Rounds in Genomic Medicine webinar series as a platform for sharing knowledge and fostering a global learning community among experts.
Illumina Inc. stock outperforms competitors on strong trading day
Illumina Inc. (ILMN) saw its stock rise by 2.30% to $166.21 on Thursday, marking its third consecutive day of gains. This performance outpaced the broader market, with the S&P 500 Index increasing by 1.75% and the Dow Jones Industrial Average rising by 1.86%. The strong trading day contributed to Illumina's positive momentum against its competitors.
Illumina Stock’s Operating Margin Climbs to 22% in Q1 2026: Is it Enough to Support a $300 Target?
Illumina's Q1 2026 results exceeded guidance, driven by strong clinical sequencing demand and NovaSeq X placements, leading to a 22% non-GAAP operating margin. The company raised its full-year operating margin guidance to 23-24%, indicating a significant recovery. Despite trailing some peers, TIKR's mid-case valuation suggests Illumina stock is undervalued, with a potential target of $228 by December 2030, offering a significant return.
